OpenAI has reportedly engaged in discussions with the U.S. Food and Drug Administration (FDA) to explore how artificial intelligence could be used to accelerate the drug approval process, according to a Wired report released Wednesday.
The talks have centered around a project referred to as cderGPT — an AI system apparently designed to support the FDA’s Center for Drug Evaluation and Research (CDER), which oversees both over-the-counter and prescription medications in the U.S. The discussions reportedly also involved participants from Elon Musk’s DOGE initiative, although the nature of their involvement is not fully clear.
While drug development often spans over a decade, the focus of cderGPT seems to be on streamlining specific late-stage regulatory processes. OpenAI’s generative AI capabilities could help analyze and summarize massive datasets, clinical trials, or regulatory documents — potentially cutting down review times.
However, the use of AI in such high-stakes areas still raises significant concerns, particularly around reliability, transparency, and accountability. Regulatory bodies like the FDA will need to rigorously test and monitor any AI tools before they are integrated into critical decision-making processes.
Also Read : Employer.com Acquires MainStreet.com to Expand Back Office Automation Platform
